Divi’s Laboratories Ltd., established in 1990 and headquartered in Hyderabad, India, is a leading global pharmaceutical company specializing in manufacturing Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients. It operates in three key segments: producing 30 large-volume generic APIs with 10 more in R&D, providing custom synthesis for tailored API and intermediate solutions for 12 of the top 20 Big Pharma companies, and manufacturing nutraceutical ingredients like Beta-Carotene and Lycopene at its Vishakhapatnam facility. With two advanced manufacturing units in Hyderabad and Vishakhapatnam, Divi’s is a top global API manufacturer, generating ~$1.2 billion in revenue and employing ~17,000 people. The company exports to over 100 countries, focusing on regulated markets like the US and Europe, with facilities compliant with USFDA, EU GMP, and HEALTH CANADA standards. Financially, Divi’s reported a market capitalization of ₹1,42,910 crore (as of April 2025), with a Q3 2024 net profit of ₹594 crore and revenue of ₹2,379 crore. Despite a modest sales growth of 9.45% over five years, it maintains a healthy dividend payout of 40.5%. Divi’s continues to innovate in sustainable manufacturing and strengthen its global footprint through strategic partnerships and a robust R&D pipeline.